Organovo Holdings Stock Today
| ONVO Stock | USD 0.44 0.01 2.42% |
Performance0 of 100
| Odds Of DistressOver 81
|
Organovo Holdings is selling at 0.4404 as of the 28th of November 2024; that is 2.42 percent increase since the beginning of the trading day. The stock's open price was 0.43. Organovo Holdings has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Organovo Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of February 2012 | Category Healthcare | Classification Health Care |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. The company was incorporated in 2007 and is headquartered in Solana Beach, California. Organovo Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 15.37 M outstanding shares of which 145.25 K shares are now shorted by private and institutional investors with about 1.97 trading days to cover. More on Organovo Holdings
Moving together with Organovo Stock
| 0.85 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.61 | INKT | Mink Therapeutics | PairCorr |
Moving against Organovo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Organovo Stock Highlights
| Chairman | Keith Murphy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOrganovo Holdings can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Organovo Holdings' financial leverage. It provides some insight into what part of Organovo Holdings' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organovo Holdings (ONVO) is traded on NASDAQ Exchange in USA. It is located in 11555 Sorrento Valley Road, San Diego, CA, United States, 92121 and employs 12 people. Organovo Holdings is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.56 M. Organovo Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 15.37 M outstanding shares of which 145.25 K shares are now shorted by private and institutional investors with about 1.97 trading days to cover.
Organovo Holdings currently holds about 26.19 M in cash with (14.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Organovo Holdings Probability Of Bankruptcy
Ownership AllocationOrganovo Holdings owns a total of 15.37 Million outstanding shares. Roughly 82.1 pct. of Organovo Holdings outstanding shares are held by general public with 2.02 % owned by insiders and only 15.88 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Organovo Ownership Details
Organovo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Xtx Topco Ltd | 2024-09-30 | 17.5 K | |
| Ubs Group Ag | 2024-06-30 | 14.4 K | |
| Tower Research Capital Llc | 2024-06-30 | 9.1 K | |
| Acadian Asset Management Llc | 2024-06-30 | 2.5 K | |
| Hanson Mcclain Inc | 2024-09-30 | 2.5 K | |
| Citadel Advisors Llc | 2024-09-30 | 2.3 K | |
| Albion Financial Group (utah) | 2024-06-30 | 1.9 K | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 1 K | |
| Quintet Private Bank (europe) Sa | 2024-09-30 | 500 | |
| Armistice Capital, Llc | 2024-09-30 | 1.2 M | |
| Prescott Group Capital Management Llc | 2024-09-30 | 414 K |
Organovo Holdings Historical Income Statement
Organovo Stock Against Markets
Organovo Holdings Corporate Management
| Vaidehi Joshi | Director Director | Profile | |
| MS JD | Gen Sec | Profile | |
| Curtis Tyree | Senior Development | Profile | |
| Jeffrey Miner | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organovo Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Organovo Stock, please use our How to Invest in Organovo Holdings guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organovo Holdings. If investors know Organovo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organovo Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.04) | Revenue Per Share 0.008 | Quarterly Revenue Growth (0.48) | Return On Assets (0.89) | Return On Equity (2.07) |
The market value of Organovo Holdings is measured differently than its book value, which is the value of Organovo that is recorded on the company's balance sheet. Investors also form their own opinion of Organovo Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organovo Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organovo Holdings' market value can be influenced by many factors that don't directly affect Organovo Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organovo Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organovo Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organovo Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.